Lee C. Goddard
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lee C. Goddard has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Wolfgang A. Tomé
Montefiore Medical Center, Department of Radiation Oncology, Bronx, NY, USA; Albert Einstein College of Medicine, Institute for Onco-Physics, Bronx, NY, USA
3 shared publications - Amar Basavatia
Department of Radiation Oncology Montefiore Medical Center Bronx NY USA
2 shared publications Wolfgang A Tomé
Radiation Oncology, Montefiore Medical Center, Bronx, USA
2 shared publicationsAmar Basavatia
Radiation Oncology, Montefiore Medical Center, Bronx, USA
1 shared publicationByung-Han Rhieu
Department of Radiation Oncology Montefiore Medical Center Bronx USA
1 shared publication- Derek A Fiedler
Radiation Oncology, Montefiore Medical Center, Bronx, USA
1 shared publication
Latest Publications
- Open Access
- 18 July 2025
- Published by Springer Nature in Cureus
- Vol. 17 (7)
An Investigation of the Dosimetric Uncertainties in the myOSLchip System: The Impact of Contributing Factors on Measurement Accuracy
The use of in vivo dosimetry (IVD) is integral to radiation oncology, particularly for treatments involving custom boluses or superficial electron lesions. In this report, the “myOSLchip” system, comprising beryllium oxide (BeO)-based optically stimulated luminescent chips and hand-held readers, was evaluated for clinical use. Each 4.7 × 0.5 mm chip, housed in plastic with an effective measurement point 1 mm below the surface, was calibrated under standard 6 megavoltage (MV) photon conditions using a 10 × 10 cm² field at 100 cm SSD and 1.5 cm depth in solid water. Calibration factors were assessed for energy dependence, dose linearity, time to readout, repeat measurements, and angular dependence. Results showed high measurement accuracy and linearity up to 10 Gy, with separate calibration factors needed per reader. The chips exhibited significant under-response at low energies (down to 16.82 keV), but minor variation in the megavoltage range for both photons and electrons. Repeat use showed an average signal loss of 1.2% after the first bleaching and 0.35% per subsequent cycle. A stable readout required at least four hours post-irradiation, with earlier readings (30-60 minutes) showing 2-3% error. No angular dependence was observed. With appropriate calibration and consideration of these factors, the myOSLchip system delivers dose measurements within the clinically accepted 3-5% accuracy range.
- 18 July 2025
- Published by Springer Nature in Cureus
- Vol. 17 (7)
Open AccessAn Investigation of the Dosimetric Uncertainties in the myOSLchip System: The Impact of Contributing Factors on Measurement Accuracy
The use of in vivo dosimetry (IVD) is integral to radiation oncology, particularly for treatments involving custom boluses or superficial electron lesions. In this report, the “myOSLchip” system, comprising beryllium oxide (BeO)-based optically stimulated luminescent chips and hand-held readers, was evaluated for clinical use. Each 4.7 × 0.5 mm chip, housed in plastic with an effective measurement point 1 mm below the surface, was calibrated under standard 6 megavoltage (MV) photon conditions using a 10 × 10 cm² field at 100 cm SSD and 1.5 cm depth in solid water. Calibration factors were assessed for energy dependence, dose linearity, time to readout, repeat measurements, and angular dependence. Results showed high measurement accuracy and linearity up to 10 Gy, with separate calibration factors needed per reader. The chips exhibited significant under-response at low energies (down to 16.82 keV), but minor variation in the megavoltage range for both photons and electrons. Repeat use showed an average signal loss of 1.2% after the first bleaching and 0.35% per subsequent cycle. A stable readout required at least four hours post-irradiation, with earlier readings (30-60 minutes) showing 2-3% error. No angular dependence was observed. With appropriate calibration and consideration of these factors, the myOSLchip system delivers dose measurements within the clinically accepted 3-5% accuracy range.
- Open Access
- 28 May 2025
- Published by Springer Nature in Cureus
- Vol. 17 (5) , e84971
Real-Time Adaptive Respiratory Motion Compensation With Stent-Based Tracking
Stereotactic body radiation therapy (SBRT) offers a promising treatment option for locally advanced pancreatic cancer, but its precision is challenged by respiratory-induced tumor motion. The Radixact Synchrony system integrates real-time motion tracking using internal and external surrogates, potentially enabling reduced treatment margins. In this case study, we report on an 85-year-old female patient with pancreatic cancer who underwent SBRT planning using an implanted biliary stent as a surrogate for tumor motion tracking. Initial assessments, including 4DCT analysis and Synchrony simulation, indicated minimal motion discrepancy between the stent and tumor, supporting its use as a tracking target. However, at the time of treatment, a ~25° rotation of the stent and intermittent external LED signal interruptions impaired motion model accuracy, leading to repeated tracking failures and treatment abortion. The patient was subsequently treated using a free-breathing internal target volume approach. This case highlights both the potential and limitations of using biliary stents as surrogates in real-time motion-adaptive SBRT. It underscores the need for robust quality assurance, improved tracking technologies, and consideration of online adaptive strategies to account for anatomical and surrogate variability. Further investigation is warranted to optimize motion management in pancreatic SBRT utilizing stents as tracking target surrogates.
- 28 May 2025
- Published by Springer Nature in Cureus
- Vol. 17 (5) , e84971
Open AccessReal-Time Adaptive Respiratory Motion Compensation With Stent-Based Tracking
Stereotactic body radiation therapy (SBRT) offers a promising treatment option for locally advanced pancreatic cancer, but its precision is challenged by respiratory-induced tumor motion. The Radixact Synchrony system integrates real-time motion tracking using internal and external surrogates, potentially enabling reduced treatment margins. In this case study, we report on an 85-year-old female patient with pancreatic cancer who underwent SBRT planning using an implanted biliary stent as a surrogate for tumor motion tracking. Initial assessments, including 4DCT analysis and Synchrony simulation, indicated minimal motion discrepancy between the stent and tumor, supporting its use as a tracking target. However, at the time of treatment, a ~25° rotation of the stent and intermittent external LED signal interruptions impaired motion model accuracy, leading to repeated tracking failures and treatment abortion. The patient was subsequently treated using a free-breathing internal target volume approach. This case highlights both the potential and limitations of using biliary stents as surrogates in real-time motion-adaptive SBRT. It underscores the need for robust quality assurance, improved tracking technologies, and consideration of online adaptive strategies to account for anatomical and surrogate variability. Further investigation is warranted to optimize motion management in pancreatic SBRT utilizing stents as tracking target surrogates.
- Open Access
- 13 April 2025
- Published by Springer Nature in Cureus
- Vol. 17 (4) , e82197
Real-Time Adaptive Motion Management in Prostate Stereotactic Body Radiation Therapy: Clinical and Dosimetric Analysis of 25 Patients
Purpose: Stereotactic body radiation therapy (SBRT) is a well-established treatment for localized prostate cancer, offering excellent tumor control with reduced treatment fractions. However, prostate motion due to physiological processes poses a challenge to precise dose delivery. This study evaluates the dosimetric outcomes, prostate-specific antigen (PSA) response, and toxicity profile of prostate SBRT using real-time adaptive motion management with the Radixact Synchrony system (Accuray Inc., Madison, WI). Methods: A retrospective analysis was conducted on 25 prostate cancer patients treated with SBRT (40 Gy in 5 fractions) using the Radixact Synchrony system between January 2021 and December 2023. All patients underwent CT simulation with fiducial markers, and 24/25 patients had MRI fusion for target and organ-at-risk (OAR) delineation. Treatment plans were generated using either the “Classic” or “VOLO Ultra” algorithms. Intrafraction prostate motion was analyzed, and toxicity was assessed using the Common Terminology Criteria for Adverse Events (CTCAE) v4.03 scale at regular follow-up intervals. Results: The median clinical target volume (CTV) for the prostate was 46.8 cm³ (range, 22.6-107.3 cm³), and the median pre-treatment PSA was 6.52 ng/mL. All plans achieved favorable target coverage while adhering to OAR dose constraints. The median post-treatment PSA value was 0.30 ng/mL with a median follow-up time of 28 months, with all patients achieving PSA levels below 2.0 ng/mL at 15 months. Motion >2 mm was observed in at least one treatment fraction for all but one patient. Real-time adaptive motion management successfully corrected for prostate displacement, with an average imaging interval of 8.4 seconds. A total of 14 patients reported new grade 1 genitourinary (GU) symptoms, and three patients experienced grade 2 GU toxicity post-treatment. Conclusion: Prostate SBRT with real-time adaptive motion management using the Radixact Synchrony system achieves excellent target coverage while mitigating the effects of intrafraction motion. The observed PSA response supports its efficacy, and OAR dose metrics remain within acceptable limits. While real-time motion adaptation was beneficial for nearly all patients, further studies with larger cohorts and patient-reported outcomes are warranted to assess long-term toxicity and quality of life.
- 13 April 2025
- Published by Springer Nature in Cureus
- Vol. 17 (4) , e82197
Open AccessReal-Time Adaptive Motion Management in Prostate Stereotactic Body Radiation Therapy: Clinical and Dosimetric Analysis of 25 Patients
Purpose: Stereotactic body radiation therapy (SBRT) is a well-established treatment for localized prostate cancer, offering excellent tumor control with reduced treatment fractions. However, prostate motion due to physiological processes poses a challenge to precise dose delivery. This study evaluates the dosimetric outcomes, prostate-specific antigen (PSA) response, and toxicity profile of prostate SBRT using real-time adaptive motion management with the Radixact Synchrony system (Accuray Inc., Madison, WI). Methods: A retrospective analysis was conducted on 25 prostate cancer patients treated with SBRT (40 Gy in 5 fractions) using the Radixact Synchrony system between January 2021 and December 2023. All patients underwent CT simulation with fiducial markers, and 24/25 patients had MRI fusion for target and organ-at-risk (OAR) delineation. Treatment plans were generated using either the “Classic” or “VOLO Ultra” algorithms. Intrafraction prostate motion was analyzed, and toxicity was assessed using the Common Terminology Criteria for Adverse Events (CTCAE) v4.03 scale at regular follow-up intervals. Results: The median clinical target volume (CTV) for the prostate was 46.8 cm³ (range, 22.6-107.3 cm³), and the median pre-treatment PSA was 6.52 ng/mL. All plans achieved favorable target coverage while adhering to OAR dose constraints. The median post-treatment PSA value was 0.30 ng/mL with a median follow-up time of 28 months, with all patients achieving PSA levels below 2.0 ng/mL at 15 months. Motion >2 mm was observed in at least one treatment fraction for all but one patient. Real-time adaptive motion management successfully corrected for prostate displacement, with an average imaging interval of 8.4 seconds. A total of 14 patients reported new grade 1 genitourinary (GU) symptoms, and three patients experienced grade 2 GU toxicity post-treatment. Conclusion: Prostate SBRT with real-time adaptive motion management using the Radixact Synchrony system achieves excellent target coverage while mitigating the effects of intrafraction motion. The observed PSA response supports its efficacy, and OAR dose metrics remain within acceptable limits. While real-time motion adaptation was beneficial for nearly all patients, further studies with larger cohorts and patient-reported outcomes are warranted to assess long-term toxicity and quality of life.
- Open Access
- 8 May 2021
- Published by Springer Nature in Cureus
- Vol. 13 (5)
Comprehensive Patient-Specific Intensity-Modulated Radiation Therapy Quality Assurance Comparing Mobius3D/FX to Conventional Methods of Evaluation
To determine the appropriateness of implementing Mobius3D/FX (Varian Medical Systems, Inc., Palo Alto, CA, USA) as not only a pretreatment secondary check but as an alternative to measurement-based patient-specific intensity-modulated radiation therapy (IMRT) quality assurance (QA). Mobius3D/FX was commissioned and stock beam models were tweaked so that an independent recalculated 3D dose distribution can be obtained. Then, 50 patient-specific treatment plans for various indications were delivered across a 2D ion chamber array, radiochromic film setup, and electronic portal imager and analyzed with MobiusFX and gamma analysis. The concordance of plans scored as passing between MobiusFX and the conventional methods of QA was determined. All analyzed treatment plans passed with a gamma passing rate >90% across all conventional QA methods, most commonly using a 3%/3mm gamma criterion except for film measurements where a 5%/3mm criterion was applied. There was good agreement and concordance between MobiusFX and conventional methods when using a 3%/3mm criteria for MobiusFX, whereas a 2%/2mm criteria appeared too stringent as it failed treatment plans deemed clinically acceptable using conventional methods. Using a 50-sample subset of clinically delivered treatment plans this non-inferiority-type comparison shows Mobius3D/FX based on log file analysis to be a suitable alternative to conventional QA methods when utilizing the 3%/3mm gamma criterion. Methods based on log file analysis can provide an opportunity for resource sparing, improving the efficiency, and workflow for evaluating IMRT treatment plans.
- 8 May 2021
- Published by Springer Nature in Cureus
- Vol. 13 (5)
Open AccessComprehensive Patient-Specific Intensity-Modulated Radiation Therapy Quality Assurance Comparing Mobius3D/FX to Conventional Methods of Evaluation
To determine the appropriateness of implementing Mobius3D/FX (Varian Medical Systems, Inc., Palo Alto, CA, USA) as not only a pretreatment secondary check but as an alternative to measurement-based patient-specific intensity-modulated radiation therapy (IMRT) quality assurance (QA). Mobius3D/FX was commissioned and stock beam models were tweaked so that an independent recalculated 3D dose distribution can be obtained. Then, 50 patient-specific treatment plans for various indications were delivered across a 2D ion chamber array, radiochromic film setup, and electronic portal imager and analyzed with MobiusFX and gamma analysis. The concordance of plans scored as passing between MobiusFX and the conventional methods of QA was determined. All analyzed treatment plans passed with a gamma passing rate >90% across all conventional QA methods, most commonly using a 3%/3mm gamma criterion except for film measurements where a 5%/3mm criterion was applied. There was good agreement and concordance between MobiusFX and conventional methods when using a 3%/3mm criteria for MobiusFX, whereas a 2%/2mm criteria appeared too stringent as it failed treatment plans deemed clinically acceptable using conventional methods. Using a 50-sample subset of clinically delivered treatment plans this non-inferiority-type comparison shows Mobius3D/FX based on log file analysis to be a suitable alternative to conventional QA methods when utilizing the 3%/3mm gamma criterion. Methods based on log file analysis can provide an opportunity for resource sparing, improving the efficiency, and workflow for evaluating IMRT treatment plans.
- Open Access
- 5 December 2018
- Published by Springer Nature in Cureus
- Vol. 10 (12) , e3693
Interstitial Surgical Cavity Sizing Applicators for the Treatment of the Breast Lumpectomy Cavity with Intraoperative Radiation Therapy
Surgical cavity sizing applicators were developed for utilization prior to intraoperative radiation therapy (IORT) of the breast lumpectomy cavity with the Zeiss INTRABEAM (Carl Zeiss Meditec AG, Jena, Germany) device. The use of these applicators minimizes the number of sterilizations of the treatment applicator, which is currently limited to 100 sterilizations per applicator. This maximizes the number of patients who can be treated with each applicator, resulting in cost savings for the treating institution.
- 5 December 2018
- Published by Springer Nature in Cureus
- Vol. 10 (12) , e3693
Open AccessInterstitial Surgical Cavity Sizing Applicators for the Treatment of the Breast Lumpectomy Cavity with Intraoperative Radiation Therapy
Surgical cavity sizing applicators were developed for utilization prior to intraoperative radiation therapy (IORT) of the breast lumpectomy cavity with the Zeiss INTRABEAM (Carl Zeiss Meditec AG, Jena, Germany) device. The use of these applicators minimizes the number of sterilizations of the treatment applicator, which is currently limited to 100 sterilizations per applicator. This maximizes the number of patients who can be treated with each applicator, resulting in cost savings for the treating institution.
- 2 March 2018
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 91 (1085) , 20180010
Comparing photon and proton-based hypofractioned SBRT for prostate cancer accounting for robustness and realistic treatment deliverability
Objective: To investigate whether photon or proton-based stereotactic body radiation therapy (SBRT is the preferred modality for high dose hypofractionation prostate cancer treatment. Achievable dose distributions were compared when uncertainties in target positioning and range uncertainties were appropriately accounted for. Methods: 10 patients with prostate cancer previously treated at our institution (Montefiore Medical Center) with photon SBRT using volumetric modulated arc therapy (VMAT) were identified. MRI images fused to the treatment planning CT allowed for accurate target and organ at risk (OAR) delineation. The clinical target volume was defined as the prostate gland plus the proximal seminal vesicles. Critical OARs include the bladder wall, bowel, femoral heads, neurovascular bundle, penile bulb, rectal wall, urethra and urogenital diaphragm. Photon plan robustness was evaluated by simulating 2 mm isotropic setup variations. Comparative proton SBRT plans employing intensity modulated proton therapy (IMPT) were generated using robust optimization. Plan robustness was evaluated by simulating 2 mm setup variations and 3% or 1% Hounsfield unit (HU) calibration uncertainties. Results: Comparable maximum OAR doses are achievable between photon and proton SBRT, however, robust optimization results in higher maximum doses for proton SBRT. Rectal maximum doses are significantly higher for Robust proton SBRT with 1% HU uncertainty compared to photon SBRT (p = 0.03), whereas maximum doses were comparable for bladder wall (p = 0.43), urethra (p = 0.82) and urogenital diaphragm (p = 0.50). Mean doses to bladder and rectal wall are lower for proton SBRT, but higher for neurovascular bundle, urethra and urogenital diaphragm due to increased lateral scatter. Similar target conformality is achieved, albeit with slightly larger treated volume ratios for proton SBRT, >1.4 compared to 1.2 for photon SBRT. Conclusion: Similar treatment plans can be generated with IMPT compared to VMAT in terms of target coverage, target conformality, and OAR sparing when range and HU uncertainties are neglected. However, when accounting for these uncertainties during robust optimization, VMAT outperforms IMPT in terms of achievable target conformity and OAR sparing. Advances in knowledge: Comparison between achievable dose distributions using modern, robust optimization of IMPT for high dose per fraction SBRT regimens for the prostate has not been previously investigated.
- 2 March 2018
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 91 (1085) , 20180010
Comparing photon and proton-based hypofractioned SBRT for prostate cancer accounting for robustness and realistic treatment deliverability
Objective: To investigate whether photon or proton-based stereotactic body radiation therapy (SBRT is the preferred modality for high dose hypofractionation prostate cancer treatment. Achievable dose distributions were compared when uncertainties in target positioning and range uncertainties were appropriately accounted for. Methods: 10 patients with prostate cancer previously treated at our institution (Montefiore Medical Center) with photon SBRT using volumetric modulated arc therapy (VMAT) were identified. MRI images fused to the treatment planning CT allowed for accurate target and organ at risk (OAR) delineation. The clinical target volume was defined as the prostate gland plus the proximal seminal vesicles. Critical OARs include the bladder wall, bowel, femoral heads, neurovascular bundle, penile bulb, rectal wall, urethra and urogenital diaphragm. Photon plan robustness was evaluated by simulating 2 mm isotropic setup variations. Comparative proton SBRT plans employing intensity modulated proton therapy (IMPT) were generated using robust optimization. Plan robustness was evaluated by simulating 2 mm setup variations and 3% or 1% Hounsfield unit (HU) calibration uncertainties. Results: Comparable maximum OAR doses are achievable between photon and proton SBRT, however, robust optimization results in higher maximum doses for proton SBRT. Rectal maximum doses are significantly higher for Robust proton SBRT with 1% HU uncertainty compared to photon SBRT (p = 0.03), whereas maximum doses were comparable for bladder wall (p = 0.43), urethra (p = 0.82) and urogenital diaphragm (p = 0.50). Mean doses to bladder and rectal wall are lower for proton SBRT, but higher for neurovascular bundle, urethra and urogenital diaphragm due to increased lateral scatter. Similar target conformality is achieved, albeit with slightly larger treated volume ratios for proton SBRT, >1.4 compared to 1.2 for photon SBRT. Conclusion: Similar treatment plans can be generated with IMPT compared to VMAT in terms of target coverage, target conformality, and OAR sparing when range and HU uncertainties are neglected. However, when accounting for these uncertainties during robust optimization, VMAT outperforms IMPT in terms of achievable target conformity and OAR sparing. Advances in knowledge: Comparison between achievable dose distributions using modern, robust optimization of IMPT for high dose per fraction SBRT regimens for the prostate has not been previously investigated.